A-Moore Fund is a venture capital firm that specializes in investing in artificial intelligence and data-driven companies, particularly those involved in drug discovery. They aim to accelerate the development of new medicines by leveraging AI technologies to improve the efficiency and effectiveness of the drug discovery process.

A-Moore Fund

aMoon is a global HealthTech and Life Sciences investment fund based in Israel. As Israel’s largest HealthTech fund, with $1.1 billion AUM, we partner with outstanding entrepreneurs who harness groundbreaking science and technology to transform healthcare.

Together with our portfolio companies, we work tirelessly to advance solutions that will help people live healthier, better lives.

We harness our unique team of over 50 scientists, physicians and entrepreneurs and our global network of investors and industry leaders to build bridges between our portfolio companies and global tech, finance and medical research hubs to help entrepreneurs turn their vision into reality.

Through our Velocity Fund we invest in companies pursuing disruptive, cutting-edge technologies as early as venture formation through Series A. Our Growth Fund invests in later-stage companies that are either generating revenue in growth rounds, pre-IPO rounds or in pivotal clinical trials.

SOPHiA GENETICS

Viracta Therapeutics

Zebra Medical Vision

Seer

CartiHeal

Sera Prognostics

Absci

Amylyx Pharmaceuticals

Ayala Pharmaceuticals

aMoon Fund

Jurgi Camblong will be presenting today at the World Economic Forum on how SOPHiA GENETICS leverages AI for groundbreaking advancements in medical research and patient care. Join the session to learn more about the growing role of AI in health care and gain unique insights from a pioneer in data-driven medicine! #WEF24 #aihealthcare #davos

Ultima Genomics and Quest Diagnostics recently announced a new collaboration to leverage Ultima's next-generation sequencing technology capabilities in single nucleotide variant (SNV) detection for solid-tumor MRD and whole-genome rare disease testing applications. 

This partnership underscores the shared dedication of both companies to accelerate the development of lab-developed tests and enhance sequencing operations with the goal of improving patient access, affordability, and outcomes.

Gilad Almogy Todd Sone Reut Shema #sequencing #genomics #HealthTech #acceleratecure

Omada Health will be the first virtual diabetes prevention, diabetes, and hypertension provider available in Amazon’s Health Condition Programs!

Through Amazon's recently launched initiative, Omada aims to increase awareness of its cardiometabolic programs and help individuals discover and enroll in virtual care benefits accessible through their employer or health plan at no extra cost. 

Congrats to Omada on this significant step towards accelerating cure and advancing healthcare accessibility and outcomes.

Sean Duffy Tomer Berkovitz Reut Shema Avital Adler, PhD #diabetes #diabetesprevention #hypertension #HealthTech #acceleratecure

Congratulations to Ibex Medical Analytics for ranking among the top 5 in DUNS 100 Best Startup Companies to Work for in 2023! Ibex's dedication to excellence goes beyond the lab, placing the wellbeing and satisfaction of the Ibex team at the core of their mission. 

Joseph (Yossi) Mossel Chaim Linhart Roy Wiesner Yaniv Sadka #AI #cancerdiagnostics #pathology #HealthTech #health #acceleratecure

2023 was a testament to our collective resilience, strength, and commitment. 

As we usher in 2024, here's to a year of shining a light on our mission to support visionary entrepreneurs, foster collaboration, and invest in groundbreaking solutions that will help people live healthier, longer, and better lives. 

Wishes for a ✨bright✨ and healthy 2024 as we continue to accelerate cure, together!

#2024goals #HealthTech #nomatterwhat

NPR's recent feature on the impossible journey of Patti Schulte vividly captures the shared struggles of many patients living with rheumatoid arthritis. From enduring pain and drug-hopping to grappling with allergies and insurance complications, her experience mirrors that of countless individuals with RA. However, amidst this agonizing cycle, a glimmer of hope emerges. PrismRA®, a novel blood test from Scipher Medicine, may herald an era of improved care for patients with rheumatoid arthritis and other autoimmune conditions. 

PrismRA®is a Molecular Signature Response Classifier (MSRC) ordered as a blood test by rheumatologists. As the first clinically validated rheumatoid arthritis test, it anticipates treatment response to widely-used RA medications, offering patients a valuable means to save time, money, and alleviate pain.

Todd Sone Osnat Hakimi #precisionmedicine #rheumatoidarthritis #HealthTech #acceleratecure

The (Un)holy Grail: With the divestment of Grail by Illumina, what’s in store for the future of DNA sequencing and Liquid Bio? Dr. Reut Shema and Dr. Yaron Daniely share their insightful analysis and predictions regarding Illumina's recently announced decision to divest GRAIL below. 

#HealthTech #dnasequencing #liquidbiopsy

Biolojic Design, Ltd. and Teva Pharmaceuticals recently announced an exclusive license agreement to develop a potential novel antibody-based therapy for the treatment of Atopic Dermatitis and Asthma.

Under this agreement, Teva Pharmaceuticals will acquire exclusive global rights to develop and commercialize Biolojic Design, Ltd.'s BD9 multibody, which was computationally designed as a multispecific antibody targeting IL-13 / TSLP (Thymic stromal lymphopoietin) for the treatment of inflammatory diseases.

Yanay Ofran Todd Sone Avital Adler, PhD #partnership #HealthTech #healthcare #health #acceleratecure

Congrats to Eleos Health for being listed in CB Insights' The Digital Health 50 as one of the most promising digital health companies in 2023!

Eleos Health is making evidence-based behavioral care a reality with their advanced AI-backed workflow solutions, allowing clinicians and providers to measurably and comparatively track treatment and progress. 

Alon Joffe Dror Zaide Alon Rabinovich Roy Wiesner Ohad Hollander #behavioralhealth #mentalhealth #AI #automation #HealthTech #healthcare #health #acceleratecure

Congratulations to Theranica Bio-Electronics Ltd. for being recognized in Fast Company's list of the 6 Next Big Things in HealthTech for 2023!

Theranica's Nerivio® stands out as a non-invasive, drug-free, personalized, and affordable wearable therapeutic product designed to prevent and treat migraines in adults and adolescents worldwide. Nerivio® is the first and only FDA-cleared device that leverages Remote Electrical Neuromodulation (REN) to prevent and treat migraines by using a smartphone app and device that wraps around a user’s upper arm, triggering a natural process in the brain to control migraine pain.

Alon Ironi Todd Sone #therapeutics #migrainerelief #noninvasive #treatment #HealthTech #healthcare #health #acceleratecure

Metric
Company Name	A-Moore Fund
Symbol
MSH ID	FUND:AMOON
Market	PRIVATE
Sector	Financial Services & Finance
Industry	Venture Capital
Country	IL
Stage
Employee Count	59
Website	amoon.fund
LinkedIn	amoon-fund
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

FUND:AMOON

A-Moore Fund

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue